




RealRate

PHARMACEUTICAL 2016

Keryx Biopharmaceuticals INC
Rank 222 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Keryx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keryx Biopharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Keryx Biopharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 92% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	249,294
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	77,606
Liabilities, Non-Current	1,076
Other Assets	1,100
Other Compr. Net Income	0
Other Expenses	6,734
Other Liabilities	93,069
Other Net Income	-11,987
Other Revenues	13,680
Property and Equipment	5,083
Research and Development	36,694
Selling, General and Administrative Expense	81,410

Output Variable	Value in 1000 USD
Assets	258,685
Liabilities	171,751
Expenses	124,838
Revenues	13,680
Stockholders Equity	86,934
Net Income	-123,145
Comprehensive Net Income	-123,145
BaseVar	290,470
ECR before Limited Liability	31%
Economic Capital Ratio	171%